HUMAN ANTI VEGF (BEVACIZUMAB BIOSIMILAR)

Human Anti-VEGF antibody is a research grade biosimilar of the monoclonal antibody drug bevacizumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic bevacizumab antibody clone. This antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-bevacizumab antibodies, for example HCA182 and HCA185. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-bevacizumab antibody in IgG1 format as a reference standard, for example HCA184 or HCA185. Bevacizumab, also known as Avastin, is a humanized monoclonal antibody (IgG1 kappa) that inhibits angiogenesis by binding to VEGF-A. VEGF-A stimulates new blood vessel formation in certain diseases, especially in cancer. Avastin is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian. This product is NOT FOR THERAPEUTIC USE. View a summary of supporting anti-bevacizumab antibody products.

• Clonality: Monoclonal
• Host: Human
• Reactivity: Human
• Isotype: IgG1

• Quantity: 0.2 mg
• Storage: +4ºC, -20ºC if preferred
• Buffer: Phosphate buffered saline, 0.02% Proclin 300

• ELISA (ELISA)